Systemic sclerosis without antinuclear antibodies or Raynaud's phenomenon: A multicentre study in the prospective EULAR scleroderma trials and research (EUSTAR) database

Rheumatology (United Kingdom)

Volumn 52, Issue 3, 2013, Pages 560-567

  Schneeberger, Daniel ^a   Tyndall, Alan ^a   Kay, Jonathan ^b   Søndergaard, Klaus H ^c   Carreira, Patricia E ^d   Morgiel, Ewa ^e   Deuschle, Katrin ^f   Derk, Chris T ^g   Widuchowska, Malgorzata ^h   Walker, Ulrich A ^a  

^a UNIVERSITY OF BASEL   (Switzerland)

^b UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^c AARHUS UNIVERSITY HOSPITAL   (Denmark)

^d HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^e WROCLAW MEDICAL UNIVERSITY   (Poland)

^f CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^g UNIVERSITY OF PENNSYLVANIA   (United States)

^h MEDICAL UNIVERSITY OF SILESIA   (Poland)

Author keywords

ANA; Differential diagnosis; Digital ulcers; Eosinophilic fasciitis; Nephrogenic systemic fibrosis; Raynaud's phenomenon; Scleroderma; Scleromyxedema; Systemic sclerosis

Indexed keywords

ANTINUCLEAR ANTIBODY; GADOLINIUM;

ARTICLE; BLADDER CARCINOMA; BREAST CANCER; CHRONIC KIDNEY DISEASE; DATA BASE; DYSPHAGIA; DYSPNEA; FEMALE; HUMAN; LUNG FIBROSIS; MAJOR CLINICAL STUDY; MALE; MEDICAL INFORMATION; MULTICENTER STUDY; MULTIPLE MYELOMA; NEPHROGENIC SYSTEMIC FIBROSIS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; QUESTIONNAIRE; RAYNAUD PHENOMENON; SCLEROMYXEDEMA; SKIN BIOPSY; SYSTEMIC SCLEROSIS;

ADULT; AGED; ANTIBODIES, ANTINUCLEAR; DATABASES, FACTUAL; FEMALE; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RAYNAUD DISEASE; SCLERODERMA, DIFFUSE;

EID: 84874062275     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/kes315     Document Type: Article

References (25)

1. Katsumoto TR, Whitfield ML, Connolly MK. The pathogenesis of systemic sclerosis. Annu Rev Pathol 2011;6: 509-37.
2. von Muhlen CA, Tan EM. Autoantibodies in the diagnosis of systemic rheumatic diseases. Semin Arthritis Rheum 1995;24:323-58.
3. Hudson M, Fritzler MJ, Baron M. Systemic sclerosis: establishing diagnostic criteria. Medicine 2010;89:159-65.
4. Chowdhury SU, Miah MA, Mahmud MI et al. Unusual presentation of progressive systemic sclerosis. Mymensingh Med J 2008;17:192-6.
5. Boin F, Hummers LK. Scleroderma-like fibrosing disorders. Rheum Dis Clin North Am 2008;34:199-220.
6. Foti R, Leonardi R, Rondinone R et al. Scleroderma-like disorders. Autoimmun Rev 2008;7:331-9.
7. Kay J. Nephrogenic systemic fibrosis: a gadolinium-associated fibrosing disorder in patients with renal dysfunction. Ann Rheum Dis 2008;67(Suppl. 3): iii66-9.
8. Girardi M, Kay J, Elston DM et al. Nephrogenic systemic fibrosis: clinicopathological definition and workup recommendations. J Am Acad Dermatol 2011;65:1095-106.
9. Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 1980;23:581-90.
10. Walker UA, Tyndall A, Czirjak L et al. Clinical risk assessment of organ manifestations in systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group database. Ann Rheum Dis 2007;66:754-63.
11. Galan A, Cowper SE, Bucala R. Nephrogenic systemic fibrosis (nephrogenic fibrosing dermopathy). Curr Opin Rheumatol 2006;18:614-7.
12. Mora GF. Systemic sclerosis: environmental factors. J Rheumatol 2009;36:2383-96.
13. Cutolo M, Pizzorni C, Tuccio M et al. Nailfold videocapillaroscopic patterns and serum autoantibodies in systemic sclerosis. Rheumatology 2004;43:719-26.
14. Kikuchi K, Hoashi T, Yazawa N, Tamaki K. Pseudoscleroderma associated with cancer. Clin Exp Dermatol 2006;31:381-3.
15. Launay D, Le BR, Hatron PY et al. Association between systemic sclerosis and breast cancer: eight new cases and review of the literature. Clin Rheumatol 2004;23: 516-22.
16. Abu-Shakra M, Guillemin F, Lee P. Cancer in systemic sclerosis. Arthritis Rheum 1993;36:460-4.
17. Kang KY, Yim HW, Kim IJ et al. Incidence of cancer among patients with systemic sclerosis in Korea: results from a single centre. Scand J Rheumatol 2009;38: 299-303.
18. Olesen AB, Svaerke C, Farkas DK, Sorensen HT. Systemic sclerosis and the risk of cancer: a nationwide population-based cohort study. Br J Dermatol 2010;163: 800-6.
19. Rosenthal AK, McLaughlin JK, Gridley G, Nyren O. Incidence of cancer among patients with systemic sclerosis. Cancer 1995;76:910-4.
20. Kyndt X, Hebbar M, Queyrel V et al. Systemic scleroderma and cancer. Search for predictive factors of cancer in 123 patients with scleroderma. Rev Med Interne 1997;18: 528-32.
21. Hill CL, Nguyen AM, Roder D, Roberts-Thomson P. Risk of cancer in patients with scleroderma: a population based cohort study. Ann Rheum Dis 2003;62:728-31.
22. Chatterjee S, Dombi GW, Severson RK, Mayes MD. Risk of malignancy in scleroderma: a population-based cohort study. Arthritis Rheum 2005;52:2415-24.
23. Derk CT, Rasheed M, Artlett CM, Jimenez SA. A cohort study of cancer incidence in systemic sclerosis. J Rheumatol 2006;33:1113-6.
24. Thomsen HS. Nephrogenic systemic fibrosis: history and epidemiology. Radiol Clin North Am 2009;47: 827-31, vi.
25. Walker UA, Knoss P, Jakobs M, Krenn V. Scleroderma and fibrosing diseases. Z Rheumatol 2009;68:312-9. www.rheumatology.